

Development of a Tie2-activating antibody for treating acute kidney injury (AKI)

MabTics Co., Ltd.



OTHERS	Candidate
Product Type	Antibody
Indication	Acute Kidney Injury (AKI)
Target	Tie2 (TEK receptor tyrosine kinase)
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Major pathogenesis of AKI induced by ischemic reperfusion injury (IRI) : kidney endothelial cells (EC) dysfunction and consequent inflammation induction • Tie2-activating antibody injection → Antibody-Tie2 binding on kidney EC → Tie2 multimerization & Tie2 signaling activation → AKT/ERK activation → Endothelial cell permeability ↓ (Kidney EC stabilization) & Inflammation ↓ → Kidney function recovery
Competitiveness	<ul style="list-style-type: none"> • A novel preventive and therapeutic approach by agonizing Tie2 receptor for kidney EC normalization • Decrease of serum creatinine/BUN and recovery of impaired kidney function • No toxicity up to 200 mg/kg (mouse, non-GLP tox study)
Development Stage	Candidate
Route of Administration	Intravenous